Mode
Text Size
Log in / Sign up

Pyruvylation of STAT1 at Lys201 suppresses type I interferon signaling during high glucose glycolysisMetabolic Changes May Influence Immune Responses and Inflammation

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that STAT1 pyruvylation at Lys201 suppresses type I interferon signaling during high glucose-enhanced glycolysis.

This systematic review explores the role of metabolite-driven protein modifications, specifically pyruvylation, in regulating immune signaling and cellular metabolism. The authors synthesize evidence regarding how glycolytic flux influences the pyruvylation landscape of various histone and non-histone substrates. They identify HAT1 and p300 as pyruvylation writers and SIRT3 as an eraser.

A key finding is that high glucose-enhanced glycolysis and pyruvate kinase M2 activity promote STAT1 pyruvylation at Lys201. This specific modification disrupts the interaction between STAT1 and STAT2, leading to the suppression of type I interferon signaling. The review notes a regulatory mechanism linking metabolic states to protein modifications, with specific signaling impacts noted for STAT1.

The authors acknowledge several limitations regarding the current understanding of pyruvylation, including questions surrounding chemistry, enzyme and substrate specificity, reader mechanisms, compartmentalization, detection strategies, and physiological relevance. While these findings suggest potential avenues for developing metabolite-based biomarkers or therapeutic strategies for inflammatory and immune-related diseases, the evidence is currently limited by these technical and biological uncertainties.

Researchers have identified a specific process called pyruvylation. This is a type of protein modification driven by metabolism. The study looked at how high glucose levels and certain metabolic activities change these proteins, specifically one called STAT1. When this happens, it can interfere with the body's ability to send out important immune signals.

The research also mapped out the broader landscape of these modifications. They identified specific enzymes that act as writers or erasers for these marks. While these findings are significant, the study is a review of current knowledge and faces several hurdles before it can be used in medicine. There are still many questions about how these processes work inside cells.

Because this research is early and involves complex cellular chemistry, it is not yet ready to change standard medical treatments. However, it provides a foundation for future work. Scientists hope to eventually use these findings to develop new ways to track or treat inflammatory and immune-related diseases.

What this means for you:
Metabolic changes can affect immune signaling, offering a potential path for future research into inflammation.

Common questions

What is pyruvylation and how does it affect the body?

Pyruvylation is a protein modification driven by metabolism. The study found that high glucose levels can lead to specific pyruvylation on a protein called STAT1. This process can disrupt certain interactions, which may suppress important immune signals known as type I interferon signaling.

Could this research lead to new treatments for inflammation?

The study suggests there is potential for developing new therapies and biomarkers for inflammatory and immune-related diseases. However, because the research is currently in the early stages of discovery, these applications are not yet ready for clinical use.

What are the limitations of this current finding?

There are several uncertainties regarding the chemistry of pyruvylation and how it functions in different parts of a cell. Because of these complexities, the findings are currently used to inform future research rather than providing immediate changes to medical practice.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedAug 2026
View Original Abstract ↓
BackgroundImmune signaling is tightly coupled to cellular metabolic state. Beyond supplying energy, metabolites can directly regulate immune responses by driving post-translational modifications of proteins and chromatin, shifting immunometabolism toward a model in which metabolic state encodes signaling outputs.FindingsProtein pyruvylation has recently emerged as a metabolite-responsive lysine modification linking glycolytic metabolism to both immune signaling and transcriptional regulation. Established examples, including histone lactylation and acylation marks linked to acetyl-CoA and crotonyl-CoA, illustrate how metabolite availability shapes chromatin state and transcriptional competence. A recent Cell study showed that high glucose-enhanced glycolysis and pyruvate kinase M2 activity promotes STAT1 pyruvylation at Lys201, thereby disrupting STAT1-STAT2 interaction and suppressing type I interferon signaling. Complementing this signaling-centered mechanism, a subsequent Nature Metabolism study systematically characterized a broader lysine pyruvylation landscape, identified histone and non-histone substrates, linked pyruvylation to glycolytic flux and pyruvyl-CoA metabolism, and implicated HAT1 and p300 as pyruvylation writers and SIRT3 as an eraser. Together, these findings expand pyruvylation from a single signaling event into an emerging metabolite-responsive regulatory system operating across protein signaling and chromatin-associated transcriptional control. In this review, we summarize the conceptual framework of metabolite-driven protein modifications, compare established marks, and discuss the remaining questions surrounding pyruvylation chemistry, enzyme and substrate specificity, reader mechanisms, compartmentalization, detection strategies, physiological relevance, and potential immunopharmacological implications.ConclusionsMetabolite-driven protein modifications represent an important regulatory layer linking metabolic rewiring to immune reprogramming. Elucidating the chemistry, regulatory machinery, substrate landscape, and physiological functions of pyruvylation will not only advance our understanding of immunometabolism but may also facilitate the development of metabolite-based biomarkers and therapeutic strategies for inflammatory and immune-related disease.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.